275 related articles for article (PubMed ID: 28427193)
21. The RNA-binding protein Sam68 regulates tumor cell viability and hepatic carcinogenesis by inhibiting the transcriptional activity of FOXOs.
Zhang T; Wan C; Shi W; Xu J; Fan H; Zhang S; Lin Z; Ni R; Zhang X
J Mol Histol; 2015 Dec; 46(6):485-97. PubMed ID: 26438629
[TBL] [Abstract][Full Text] [Related]
22. Significance of AZD1152 as a potential treatment against Aurora B overexpression in acute promyelocytic leukemia.
Ghanizadeh-Vesali S; Zekri A; Zaker F; Zaghal A; Yousefi M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Ann Hematol; 2016 Jun; 95(7):1031-42. PubMed ID: 27091351
[TBL] [Abstract][Full Text] [Related]
23. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L
Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815
[TBL] [Abstract][Full Text] [Related]
24. LincRNA-p21 activates endoplasmic reticulum stress and inhibits hepatocellular carcinoma.
Yang N; Fu Y; Zhang H; Sima H; Zhu N; Yang G
Oncotarget; 2015 Sep; 6(29):28151-63. PubMed ID: 26305675
[TBL] [Abstract][Full Text] [Related]
25. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
[TBL] [Abstract][Full Text] [Related]
26. Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R-YAP Axis.
Zhu H; Wang DD; Yuan T; Yan FJ; Zeng CM; Dai XY; Chen ZB; Chen Y; Zhou T; Fan GH; Ying M; Cao J; Luo P; Liu XJ; Hu Y; Peng Y; He Q; Yang B
Cancer Res; 2018 Jul; 78(14):3995-4006. PubMed ID: 29669759
[TBL] [Abstract][Full Text] [Related]
27. RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC).
Ezzeldin M; Borrego-Diaz E; Taha M; Esfandyari T; Wise AL; Peng W; Rouyanian A; Asvadi Kermani A; Soleimani M; Patrad E; Lialyte K; Wang K; Williamson S; Abdulkarim B; Olyaee M; Farassati F
Mol Oncol; 2014 Jul; 8(5):1043-53. PubMed ID: 24785097
[TBL] [Abstract][Full Text] [Related]
28. Derivate isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis.
Chen L; Tian H; Li M; Ge C; Zhao F; Zhang L; Li H; Liu J; Wang T; Yao M; Li J
Tumour Biol; 2016 May; 37(5):5951-61. PubMed ID: 26596832
[TBL] [Abstract][Full Text] [Related]
29. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.
Aihara A; Tanaka S; Yasen M; Matsumura S; Mitsunori Y; Murakata A; Noguchi N; Kudo A; Nakamura N; Ito K; Arii S
J Hepatol; 2010 Jan; 52(1):63-71. PubMed ID: 19913935
[TBL] [Abstract][Full Text] [Related]
30. The radiosensitizing effect of the aurora kinase inhibitors, ENMD-2076, on canine mast cell tumours in vitro.
Shiomitsu K; Sajo E; Rubin C; Sehgal I
Vet Comp Oncol; 2016 Mar; 14(1):13-27. PubMed ID: 23763774
[TBL] [Abstract][Full Text] [Related]
31. IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signaling.
Liu R; Tang C; Shen A; Luo H; Wei X; Zheng D; Sun C; Li Z; Zhu D; Li T; Wu Z
Oncotarget; 2016 Dec; 7(51):85079-85096. PubMed ID: 27835881
[TBL] [Abstract][Full Text] [Related]
32. Expression of aurora kinases: Predictor of tumor dissemination in uterine carcinosarcoma.
Han KH; Kim MA; Park NH
Histol Histopathol; 2017 Jul; 32(7):717-724. PubMed ID: 27779297
[TBL] [Abstract][Full Text] [Related]
33. The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells.
Li JP; Yang YX; Liu QL; Zhou ZW; Pan ST; He ZX; Zhang X; Yang T; Pan SY; Duan W; He SM; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1027-62. PubMed ID: 25733818
[TBL] [Abstract][Full Text] [Related]
34. Butein suppresses hepatocellular carcinoma growth via modulating Aurora B kinase activity.
Zhou Y; Li M; Yu X; Liu T; Li T; Zhou L; Liu W; Li W; Gao F
Int J Biol Sci; 2018; 14(11):1521-1534. PubMed ID: 30263005
[TBL] [Abstract][Full Text] [Related]
35. An update on targeting Hippo-YAP signaling in liver cancer.
Liu AM; Xu Z; Luk JM
Expert Opin Ther Targets; 2012 Mar; 16(3):243-7. PubMed ID: 22335485
[TBL] [Abstract][Full Text] [Related]
36. TRIP6 promotes cell proliferation in hepatocellular carcinoma via suppression of FOXO3a.
Zhao W; Dai Y; Dai T; Xie T; Su X; Li J; Zhou X; Meng K; Zhao X
Biochem Biophys Res Commun; 2017 Dec; 494(3-4):594-601. PubMed ID: 29080747
[TBL] [Abstract][Full Text] [Related]
37. Structural Biology Insight for the Design of Sub-type Selective Aurora Kinase Inhibitors.
Sarvagalla S; Coumar MS
Curr Cancer Drug Targets; 2015; 15(5):375-93. PubMed ID: 25895501
[TBL] [Abstract][Full Text] [Related]
38. Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma.
Han SX; Bai E; Jin GH; He CC; Guo XJ; Wang LJ; Li M; Ying X; Zhu Q
J Immunol Res; 2014; 2014():261365. PubMed ID: 24860833
[TBL] [Abstract][Full Text] [Related]
39. DNA-PKcs: A promising therapeutic target in human hepatocellular carcinoma?
Pascale RM; Joseph C; Latte G; Evert M; Feo F; Calvisi DF
DNA Repair (Amst); 2016 Nov; 47():12-20. PubMed ID: 27789167
[TBL] [Abstract][Full Text] [Related]
40. Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma.
Xia L; Huang W; Tian D; Zhu H; Zhang Y; Hu H; Fan D; Nie Y; Wu K
J Hepatol; 2012 Sep; 57(3):600-12. PubMed ID: 22613004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
